Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: J Stroke Cerebrovasc Dis. 2010 May 14;19(4):290–293. doi: 10.1016/j.jstrokecerebrovasdis.2009.06.001

Table 2.

Demographics

NINDS-ECASS III* Placebo NINDS-ECASS III* t-PA p
n 199 200
Age (mean±SD) 64.9 (10.8) 66 (10.1) 0.31
Gender (male) 64.8% 59.5% 0.32
Treatment 0–90 min 48.2% 54% 0.29
Treatment 90–180 min 51.8% 46.0%
Time to treatment (min) (mean±SD) 118.6 (35.7) 117.1 (37.9) 0.69
NIHSS (mean±SD) 13.8 (5.9) 12.1 (6.0) 0.0055
Blood pressure (mean±SD) 113.5 (17.6) mmHg 112.8 (17.7) mmHg 0.73
Weight (kg) 81 (18.9) 76.6 (15.3) 0.012
Current smoker 36.0% 38.9% 0.63
Diabetes 13.6 14.5 0.92
Prior stroke 25.1 27.5 0.67
Hypertension 64.5 63.8 0.98
Aspirin use 28.6 40 0.022
Atrial fibrillation 14.6 14.7 0.92
*

Patients from the NINDS sample fulfilling the ECASS III study criteria